Literature DB >> 33387158

Liver Abscess in Chronic Granulomatous Disease-Two Decades of Experience from a Tertiary Care Centre in North-West India.

Rakesh Kumar Pilania1, Amit Rawat2, Pandiarajan Vignesh1, Sandesh Guleria1, Ankur Kumar Jindal1, Gargi Das1, Deepti Suri1, Anju Gupta1, Kirti Gupta3, Koon-Wing Chan4, Yu-Lung Lau4, Kohsuke Imai5, Surjit Singh1.   

Abstract

PURPOSE: Most of the literature on liver abscess in chronic granulomatous disease (CGD) emanates from developed countries. Data from developing countries are scarce. In this study, we report clinical features, microbiological profile, and treatment difficulties encountered while managing liver abscesses in patients with CGD at a tertiary care centre in North-West India.
METHODOLOGY: Case records of children with CGD and liver abscesses at Pediatric Immunodeficiency Clinic, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India were analyzed.
RESULTS: Seven of 68 patients (10.29%) with CGD presented with hepatic abscess. One patient had 2 recurrences. All were males and age-range at presentation was 7 months-22 years. Mutation analysis was carried out in all patients-3 had defects in CYBB gene; 2 in NCF1; 2 in NCF2 gene. Staphylococcus aureus was isolated from 5 patients. Duration of antimicrobial treatment ranged from 3 weeks to 7 months. Open drainage was required in 1 patient, and 1 patient was treated with a prolonged course of prednisolone. Two children succumbed to the illness.
CONCLUSIONS: This is the largest reported experience of liver abscesses in patients with CGD from the developing world. Staphylococcus aureus was the commonest pathogen isolated. In our experience, prolonged courses of antimicrobials are usually necessary in these patients. Glucocorticoids can reduce inflammatory response and facilitate early resolution of abscesses in CGD.

Entities:  

Keywords:  Chronic granulomatous disease; corticosteroids; liver abscess; primary immunodeficiency disorder

Mesh:

Substances:

Year:  2021        PMID: 33387158     DOI: 10.1007/s10875-020-00938-9

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  1 in total

1.  Chronic granulomatous disease: the European experience.

Authors:  J Merlijn van den Berg; Elsbeth van Koppen; Anders Ahlin; Bernd H Belohradsky; Ewa Bernatowska; Lucien Corbeel; Teresa Español; Alain Fischer; Magdalena Kurenko-Deptuch; Richard Mouy; Theoni Petropoulou; Joachim Roesler; Reinhard Seger; Marie-José Stasia; Niels H Valerius; Ron S Weening; Baruch Wolach; Dirk Roos; Taco W Kuijpers
Journal:  PLoS One       Date:  2009-04-21       Impact factor: 3.240

  1 in total
  2 in total

1.  Clinical, Immunological, and Molecular Profile of Chronic Granulomatous Disease: A Multi-Centric Study of 236 Patients From India.

Authors:  Amit Rawat; Pandiarajan Vignesh; Murugan Sudhakar; Madhubala Sharma; Deepti Suri; Ankur Jindal; Anju Gupta; Jitendra Kumar Shandilya; Sathish Kumar Loganathan; Gurjit Kaur; Sanchi Chawla; Pratap Kumar Patra; Alka Khadwal; Biman Saikia; Ranjana Walker Minz; Vaishali Aggarwal; Prasad Taur; Ambreen Pandrowala; Vijaya Gowri; Mukesh Desai; Manasi Kulkarni; Gauri Hule; Umair Bargir; Priyanka Kambli; Manisha Madkaikar; Sagar Bhattad; Chetan Ginigeri; Harish Kumar; Ananthvikas Jayaram; Deenadayalan Munirathnam; Meena Sivasankaran; Revathi Raj; Ramya Uppuluri; Fouzia Na; Biju George; Harsha Prasada Lashkari; Manas Kalra; Anupam Sachdeva; Shishir Seth; Tapas Sabui; Aman Gupta; Karin van Leeuwen; Martin de Boer; Koon Wing Chan; Kohsuke Imai; Osamu Ohara; Shigeaki Nonoyama; Yu Lung Lau; Surjit Singh
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

2.  Case report: Corticosteroids as an adjunct treatment for the management of liver abscess in Papillon-Lefèvre syndrome: A report on two cases.

Authors:  Suprit Basu; Reva Tyagi; Ankur Kumar Jindal; Apurva Medha; Aaqib Zaffar Banday; Alisha Babbar; Apoorva Sharma; Rahul Mahajan; Pandiarajan Vignesh; Amit Rawat
Journal:  Front Pediatr       Date:  2022-09-20       Impact factor: 3.569

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.